The market is a leading global hub, driven by strong biotech innovation, high investment, and the presence of major pharmaceutical companies advancing RNA-based therapeutics. Growth is supported by increasing FDA approvals, expanding clinical pipelines, and rising adoption of precision medicine for testing rare genetic, cardiovascular, and oncology-related diseases.
The U.S. small interfering RNA (siRNA) refers to short double-stranded RNA molecules used in gene silencing to specifically block the expression of disease-causing genes for therapeutic purposes. The U.S. small interfering RNA (siRNA) market is growing rapidly due to strong biotechnology infrastructure, high R&D funding, and the presence of leading pharmaceutical companies developing RNA-based therapies. Increasing FDA approvals and a robust clinical trial ecosystem are accelerating commercialization. Rising adoption of precision medicine and expanding application in rare genetic, cardiovascular, and oncology diseases further support market growth, making the U.S. a global leader in siRNA innovation.
The global small interfering RNA (siRNA) market size was estimated at USD 3.9 billion in 2025 and is predicted to increase from USD 4.52 billion in 2026 to approximately USD 16.91 billion by 2035, expanding at a CAGR of 15.8% from 2026 to 2035.
The future of the small interfering RNA (siRNA) market is highly promising, driven by expanding clinical applications in oncology, rare genetic, cardiovascular, and metabolic diseases. Advancements in delivery technologies and improved drug stability are enhancing treatment effectiveness. Increasing regulatory approvals, strong R&D investments, and growing adoption of precision medicine are expected to accelerate commercialization, making siRNA a key pillar of next-generation gene-silencing therapies globally.
| Year | Genetic Diseases (No. of FDA approvals) | Chronic diseases (No. approvals) |
| 2024 | 26 | 24 |
| 2025 | 23 | 23 |
In 2024 and 2025, U.S. FDA approval data show a strong balance between genetic and chronic disease-focused therapies, reflecting the growing relevance of siRNA-based treatments. Genetic diseases accounted for 26 approvals in 2024 and 23 in 2025, while chronic diseases recorded 24 and 23 approvals, respectively. This steady pipeline highlights increasing adoption of precision medicine, where RNA-based approaches like siRNA are being explored for both rare disorders and widespread chronic conditions.
The synthetic siRNA segment dominated the U.S. small interfering RNA (siRNA) market with a revenue share of 58% in 2025 due to its high specificity in gene silencing and strong clinical validation through multiple approved therapies. It offers effective targeting of disease-causing genes with improved safety and efficacy. Growing in treating generic, cardiovascular, and rare diseases, along with advancements in delivery technologies, has further strengthened its leading position in the market.
The lipid-based delivery segment held a dominant share of 46% in the U.S. small interfering RNA (siRNA) market in 2025 due to its ability to protect RNA molecules from degradation and ensure efficient cellular uptake. Lipid nanoparticles enhance stability and targeting, especially for liver-based therapies. Their proven success in approving siRNA drugs and compatibility with large-scale manufacturing further drive widespread adoption and market leadership.
The therapeutic segment led the market with a share of 52% in 2025 and is expected to grow at the fastest CAGR in the U.S. small interfering RNA (siRNA) market during the forecast period due to increasing clinical use of gene-silencing therapies for treating rare genetic, cardiovascular, and metabolic diseases. A growing number of approved siRNA drugs, along with a strong pipeline of candidates in late trials, supported its dominance. Advancements in delivery technologies and rising demand for targeted, precision medicine approaches further accelerated adoption in therapeutic applications.
The pharmaceutical & biotechnology segment held a dominant share of 49% in 2025 and is expected to grow at the fastest CAGR in the U.S. small interfering RNA (siRNA) market during the forecast period due to strong R&D investments, advanced drug development capabilities, and extensive clinical trial activity. These companies lead in developing and commercializing RNA-based therapies for genetic and chronic diseases. Their robust pipelines, strategic collaboration, and expertise in biologics manufacturing further reinforced their leading market position.
The intravenous segment held a dominant share of 38% in 2025 due to its ability to deliver siRNA therapies directly into the bloodstream, ensuring rapid distribution and precise dosing. It is widely used for approved treatments, particularly liver-targeted therapies. Strong compatibility with lipid nanoparticle systems and preference in clinical settings further its leading position.
Leading companies in the market include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Dicerna Pharmaceuticals, Pfizer, and Novartis. These players drive growth through RNA-based drug development, focusing on gene-silencing therapies for rare genetic, cardiovascular, and oncology diseases, while advancing delivery technologies and expanding precision medicine applications in the U.S. market.
By Type
By Delivery Method
By Application
By End User
By Route of Administration
